2024 ICD-10-CM Diagnosis Code C58

Malignant neoplasm of placenta

ICD-10-CM Code:
C58
ICD-10 Code for:
Malignant neoplasm of placenta
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Chronic
Code Navigator:

Code Classification

  • Neoplasms
    (C00–D49)
    • Malignant neoplasms of female genital organs
      (C51-C58)
      • Malignant neoplasm of placenta
        (C58)

C58 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of placenta. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

The code C58 is applicable to female patients aged 12 through 55 years inclusive. It is clinically and virtually impossible to use this code on a non-female patient outside the stated age range.

The following anatomical sites found in the Table of Neoplasms reference this diagnosis code given the correct histological behavior: Neoplasm, neoplastic fetal membrane or Neoplasm, neoplastic placenta .

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Choriocarcinoma
  • Choriocarcinoma
  • Choriocarcinoma
  • Choriocarcinoma of placenta
  • Epithelioid trophoblastic tumor
  • Gestational choriocarcinoma
  • Gestational trophoblastic disease
  • Gestational trophoblastic disease
  • Gestational trophoblastic neoplasia
  • Gestational trophoblastic neoplasia
  • Malignant neoplastic disease in pregnancy
  • Malignant neoplastic disease in pregnancy
  • Malignant neoplastic disease in pregnancy
  • Malignant neoplastic disease in pregnancy
  • Neoplasm of placenta
  • Neoplasm of placenta
  • Primary malignant neoplasm of placenta

Clinical Classification

Clinical Information

  • Abruptio Placentae

    premature separation of the normally implanted placenta from the uterus. signs of varying degree of severity include uterine bleeding, uterine muscle hypertonia, and fetal distress or fetal death.
  • Annexin A3

    a protein of the annexin family that catalyzes the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.
  • Annexin A4

    protein of the annexin family originally isolated from the electric organ of the electric ray torpedo marmorata. it has been found in a wide range of mammalian tissue where it is localized to the apical membrane of polarized epithelial cells.
  • Annexin A5

    a protein of the annexin family isolated from human placenta and other tissues. it inhibits cytosolic phospholipase a2, and displays anticoagulant activity.
  • Cadherins

    calcium-dependent cell adhesion proteins. they are important in the formation of adherens junctions between cells. cadherins are classified by their distinct immunological and tissue specificities, either by letters (e- for epithelial, n- for neural, and p- for placental cadherins) or by numbers (cadherin-12 or n-cadherin 2 for brain-cadherin). cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
  • Chorionic Villi

    threadlike vascular projections of the chorion. chorionic villi may be free or embedded within the decidua forming the site for exchange of substances between fetal and maternal blood (placenta).
  • Cord Blood Stem Cell Transplantation

    transplantation of stem cells collected from the fetal blood remaining in the umbilical cord and the placenta after delivery. included are the hematopoietic stem cells.
  • Eutheria

    mammals which nourish their young in utero by means of a complex placenta, and give birth to their young alive. they include primates; carnivora, whales; ruminants; bats; and rodents.
  • Folate Receptor 2

    a subtype of gpi-anchored folate receptors that is expressed in placenta and hematopoietic cells.
  • Ichthyosis, X-Linked

    chronic form of ichthyosis that is inherited as a sex-linked recessive trait carried on the x-chromosome and transmitted to the male offspring. it is characterized by severe scaling, especially on the extremities, and is associated with steroid sulfatase deficiency.
  • Perilipin-3

    a perilipin that localizes to lipid droplets; cytoplasm; endosomes; and plasma membrane, especially in macrophages. it functions as a transporter of free fatty acids to lipid droplets to promote their biogenesis and growth. it is also required for the transport of the mannose-6-phosphate receptor from endosomes to the trans-golgi network. its structure consists of four helix bundles that interact with the hydrophobic lipid droplet surface.
  • Placenta

    a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. it includes a fetal portion (chorionic villi) derived from trophoblasts and a maternal portion (decidua) derived from the uterine endometrium. the placenta produces an array of steroid, protein and peptide hormones (placental hormones).
  • Placenta Accreta

    abnormal placentation in which all or parts of the placenta are attached directly to the myometrium due to a complete or partial absence of decidua. it is associated with postpartum hemorrhage because of the failure of placental separation.
  • Placenta Diseases

    pathological processes or abnormal functions of the placenta.
  • Placenta Growth Factor

    an angiogenic protein belonging to the vascular endothelial growth factor family of growth factors originally isolated and cloned from human placental cdna library. there are four isoforms of plgf 1-4 which result from alternative splicing. placenta growth factor is secreted as a glycosylated homodimer which acts as a mitogen for endothelial cells, and its expression is markedly upregulated during hypoxia and in tissue inflammation and cancer.
  • Placenta Previa

    abnormal placentation in which the placenta implants in the lower segment of the uterus (the zone of dilation) and may cover part or all of the opening of the cervix. it is often associated with serious antepartum bleeding and premature labor.
  • Placenta, Retained

    a placenta that fails to be expelled after birth of the fetus. a placenta is retained when the uterus fails to contract after the delivery of its content, or when the placenta is abnormally attached to the myometrium.
  • Placental Circulation

    the circulation of blood, of both the mother and the fetus, through the placenta.
  • Placental Extracts

    extracts prepared from placental tissue; they may contain specific but uncharacterized factors or proteins with specific activities.
  • Placental Function Tests

    methods used for the assessment of placental function.
  • Placental Hormones

    hormones produced by the placenta include chorionic gonadotropin, and placental lactogen as well as steroids (estrogens; progesterone), and neuropeptide hormones similar to those found in the hypothalamus (hypothalamic hormones).
  • Placental Insufficiency

    failure of the placenta to deliver an adequate supply of nutrients and oxygen to the fetus.
  • Placental Lactogen

    a polypeptide hormone of approximately 25 kda that is produced by the syncytiotrophoblasts of the placenta, also known as chorionic somatomammotropin. it has both growth hormone and prolactin activities on growth, lactation, and luteal steroid production. in women, placental lactogen secretion begins soon after implantation and increases to 1 g or more a day in late pregnancy. placental lactogen is also an insulin antagonist.
  • Placentation

    the development of the placenta, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and fetus. the process begins at fertilization, through the development of cytotrophoblasts and syncytiotrophoblasts, the formation of chorionic villi, to the progressive increase in blood vessels to support the growing fetus.
  • Plasminogen Inactivators

    important modulators of the activity of plasminogen activators. the inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.
  • Pregnancy Proteins

    proteins produced by organs of the mother or the placenta during pregnancy. these proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)
  • Pregnancy Trimester, First

    the beginning third of a human pregnancy, from the first day of the last normal menstrual period (menstruation) through the completion of 14 weeks (98 days) of gestation.
  • S100 Calcium-Binding Protein A4

    an s100 protein characterized by four helix bundles that form n- and c-terminal ef hand motifs. it functions as a homodimer and interacts with both intracellular and extracellular signaling proteins. aberrant s100a4 activity is associated with neoplasm metastasis; fibrosis; and rheumatoid arthritis.
  • Trophoblastic Tumor, Placental Site

    an uncommon variant of choriocarcinoma. it is composed almost entirely of mononuclear cytotrophoblasts (trophoblasts). because its secretion of hcg (chorionic gonadotropin) is low, a large tumor may develop before the hcg can be detected.
  • Umbilical Cord Clamping

    method of placing clamps on the umbilical cord before cutting after birth.
  • Choriocarcinoma

    a malignant metastatic form of trophoblastic tumors. unlike the hydatidiform mole, choriocarcinoma contains no chorionic villi but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (trophoblasts). it is characterized by the large amounts of chorionic gonadotropin produced. tissue origins can be determined by dna analyses: placental (fetal) origin or non-placental origin (choriocarcinoma, non-gestational).
  • Choriocarcinoma, Non-gestational

    a highly malignant choriocarcinoma derived from the non-placental origin such as the totipotent cells in the testis, the ovary, and the pineal gland. it produces high levels of chorionic gonadotropin and can metastasize widely through the bloodstream to the lungs, brain, liver, bone, and other viscera by the time of diagnosis.
  • Gestational Trophoblastic Disease

    a group of diseases arising from pregnancy that are commonly associated with hyperplasia of trophoblasts (trophoblast) and markedly elevated human chorionic gonadotropin. they include hydatidiform mole, invasive mole (hydatidiform mole, invasive), placental-site trophoblastic tumor (trophoblastic tumor, placental site), and choriocarcinoma. these neoplasms have varying propensities for invasion and spread.
  • Fallopian Tube Gestational Choriocarcinoma|Gestational Choriocarcinoma of Fallopian Tube|Gestational Choriocarcinoma of the Fallopian Tube

    a malignant trophoblastic tumor that arises from the fallopian tube during pregnancy.
  • Gestational Choriocarcinoma

    a rare, highly malignant epithelial tumor that develops from a hydatidiform mole (50%), following abortion (25%), or during normal pregnancy (22%). it is characterized by the presence of invasive and anaplastic trophoblastic tissue composed of intermediate trophoblastic cells, cytotrophoblasts and syncytiotrophoblasts, abundant vascularity, and secretion of human chorionic gonadotropin. because of rapid growth and a high propensity for hemorrhage, this neoplasm often constitutes a medical emergency.
  • Ovarian Gestational Choriocarcinoma|Gestational Ovarian Choriocarcinoma

    a rare malignant trophoblastic tumor that arises from the ovary as a result of ectopic ovarian pregnancy. there is no germ cell component present.
  • Uterine Corpus Choriocarcinoma|Gestational Uterine Corpus Choriocarcinoma|Uterine Corpus Gestational Choriocarcinoma

    an aggressive malignant tumor arising from trophoblastic cells in the uterus during pregnancy. approximately half of the cases develop from a complete hydatidiform mole. there is often marked elevation of human chorionic gonadotropin (hcg) in the blood. choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.

Tabular List of Diseases and Injuries

The following annotation back-references are applicable to this diagnosis code. The Tabular List of Diseases and Injuries is a list of ICD-10-CM codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more.


Includes

Includes
This note appears immediately under a three character code title to further define, or give examples of, the content of the category.
  • choriocarcinoma NOS
  • chorionepithelioma NOS

Type 1 Excludes

Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • chorioadenoma destruens D39.2
  • hydatidiform mole NOS O01.9
  • invasive hydatidiform mole D39.2
  • male choriocarcinoma NOS C62.9
  • malignant hydatidiform mole D39.2

Index to Diseases and Injuries References

The following annotation back-references for this diagnosis code are found in the injuries and diseases index. The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10-CM code(s).

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Maternity diagnoses - The Medicare Code Editor detects inconsistencies in maternity cases by checking a patient's age and any diagnosis on the patient's record. The maternity code edits apply to patients age ange is 9–64 years inclusive (e.g., diabetes in pregnancy, antepartum pulmonary complication).
  • Diagnoses for females only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to FEMALES only .

Convert C58 to ICD-9-CM

  • ICD-9-CM Code: 181 - Malignant neopl placenta

Table of Neoplasms

This code is referenced in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»Neoplasm, neoplastic
  »fetal membrane
C58C79.82D07.0D26.7D39.2D49.59
»Neoplasm, neoplastic
  »placenta
C58C79.82D07.0D26.7D39.2D49.59

Patient Education


Tumors and Pregnancy

Tumors during pregnancy are rare, but they can happen. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. The most common cancers in pregnancy are breast cancer, cervical cancer, lymphoma, and melanoma. Cancer itself rarely harms the baby, and some cancer treatments are safe during pregnancy. You and your health care provider will work together to find the best treatment. Your options will depend on how far along the pregnancy is, as well as the type, size, and stage of your cancer.

Another type of tumor that women can get is called a gestational trophoblastic disease (GTD). It happens when a fertilized egg doesn't become a fetus. GTD is not always easy to find. It is usually benign, but some types can be malignant. The most common type of GTD is a molar pregnancy. In its early stages, it may look like a normal pregnancy. You should see your health care provider if you have vaginal bleeding (not menstrual bleeding).

Treatment depends on the type of tumor, whether it has spread to other places, and your overall health.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.